Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.36 USD
Change Today +0.05 / 2.16%
Volume 1.8M
VVUS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for vivus inc (VVUS)

VIVUS Inc. may have more financial risk than other companies in the Pharmaceuticals industry as it is one of the most highly leveraged with a Debt to Total Capital ratio of 73.41%. This ratio actually increased over the last year. However, an examination of near-term assets and liabilities shows that there are enough liquid assets to satisfy current obligations. Accounts Receivable are among the industry's worst with 38.05 days worth of sales outstanding. This implies that revenues are not being collected in an efficient manner. Last, VIVUS Inc. is among the most efficient in its industry at managing inventories, with only 425.75 days of its Cost of Goods Sold tied up in inventory.
Currency in
Millions of US Dollars
As of:Dec 31
2011
Restated
Dec 31
2012
Restated
Dec 31
2013
Reclassified
Dec 31
2014
4 Year
Trend
Assets    
Cash and Equivalents39.658.6103.383.2
Short-Term Investments107.3156.0240.0216.4
TOTAL CASH AND SHORT TERM INVESTMENTS146.8214.6343.3299.6
Accounts Receivable--2.812.211.6
Other Receivables0.7------
TOTAL RECEIVABLES0.72.812.211.6
Inventory3.125.448.534.4
Prepaid Expenses1.119.213.111.6
Other Current Assets----6.81.2
TOTAL CURRENT ASSETS151.7261.9423.9358.4
Gross Property Plant and Equipment1.53.44.24.4
Accumulated Depreciation-1.2-1.4-2.3-3.1
NET PROPERTY PLANT AND EQUIPMENT0.32.02.01.3
Deferred Charges, Long Term----4.63.4
Other Long-Term Assets--0.31.33.8
TOTAL ASSETS152.1264.1431.8366.9
    
LIABILITIES & EQUITY    
Accounts Payable2.925.410.810.4
Accrued Expenses6.413.819.413.8
Current Portion of Long-Term Debt/Capital Lease------10.5
Other Current Liabilities, Total1.60.94.63.3
Unearned Revenue, Current--1.217.319.4
TOTAL CURRENT LIABILITIES11.041.252.057.4
Long-Term Debt----213.1217.3
Unearned Revenue, Non-Current----10.48.9
Other Non-Current Liabilities----3.00.8
TOTAL LIABILITIES11.041.2278.4284.4
Common Stock0.10.10.10.1
Additional Paid in Capital487.2708.9813.8825.7
Retained Earnings-346.3-486.1-660.6-743.2
Comprehensive Income and Other0.00.00.10.0
TOTAL COMMON EQUITY141.1222.9153.482.5
TOTAL EQUITY141.1222.9153.482.5
TOTAL LIABILITIES AND EQUITY152.1264.1431.8366.9
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VVUS:US $2.36 USD +0.05

VVUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.21 USD -0.10
GlaxoSmithKline Consumer Healthcare Ltd 6,396 INR -3.25
Novo Nordisk A/S kr369.70 DKK -0.90
Orexigen Therapeutics Inc $6.61 USD -0.11
Takeda Pharmaceutical Co Ltd ¥6,193 JPY +36.00
View Industry Companies
 

Industry Analysis

VVUS

Industry Average

Valuation VVUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.1x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIVUS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.